Imagine a smart bandage that acts like a powerful vacuum for bacteria while helping the skin knit back together. It uses tiny particles to kill germs much more effectively than current options. This helps deep wounds, like those from diabetes, heal faster and prevents the need for surgery to remove limbs.
Current wound care solutions are inefficient, leading to a surge in limb amputations for chronic patients. This results in massive healthcare costs and poor patient outcomes.
An Antibacterial Wound Dressing (AWD) using synergistic nanoparticles and a 3D low-density polyethylene substrate.
If you are a manufacturer dealing with stagnant growth in antibacterial dressings — this project developed a nanoparticle-based dressing that removes bacterial infection 8x better than current best options. This allows for a high-efficacy product in a market projected to reach 4.2 billion euros by 2026.
If you are a hospital dealing with high rates of diabetic foot ulcer complications — this project developed a dressing that heals these ulcers 2 times faster. This can help reduce the 100 billion euros in additional healthcare costs associated with amputations.
If you are a distributor dealing with a need for first-in-class wound care products — this project developed an Antibacterial Wound Dressing (AWD) with a B2B model designed for hospital reach. It offers a competitive edge through high efficacy and low cost.
Based on available project data, the company's value propositions are high efficacy and low cost, aiming to lower overall healthcare costs.
The project has achieved a design freeze and solved quality challenges regarding batch-to-batch variation of metal concentrations by adjusting electrospinning parameters.
The company has stated they have a priority for intellectual property to protect their first-in-class wound care products.
The project established QMS documents according to ISO13485 and performed most regulatory tests required for CE marking.
The project period runs from 2023-04-01 to 2026-03-31, with pilot clinical trials already completed.
The project is led by a single SME, Nanordica Medical OU from Estonia. With a 100% industry ratio and no university or research partners, the project is heavily focused on commercialization and rapid product development rather than basic research.
Contact Nanordica Medical OU in Estonia
Contact us to explore licensing opportunities for this nanoparticle wound care technology.
